Fusing AI and Expertise: Iterative Health's Strategic Cardiology Move

CAMBRIDGE, Mass. – August 11, 2026 – In a move that signals a significant strategic escalation in the cardiology research sector, health technology firm Iterative Health has appointed Dr. Samin K. Sharma as a scientific advisor and honorary chair of Interventional Cardiology. The appointment of the world-renowned physician from The Mount Sinai Hospital is more than a high-profile addition to an advisory board; it represents a calculated fusion of elite clinical expertise with a scalable, AI-powered technology platform, aimed at solving one of the most persistent bottlenecks in modern medicine: the slow, costly, and often inefficient clinical trial process.

For leaders tracking the intersection of innovation and execution, this development is a critical case study. It’s a deliberate effort to move beyond the hype of artificial intelligence and ground it in the complex realities of patient care. As Iterative Health doubles down on its cardiology ambitions, the addition of Dr. Sharma provides a crucial layer of clinical authority, aiming to translate technological promise into tangible results for sponsors, research sites, and ultimately, patients.

A Strategic Play in a High-Stakes Field

Iterative Health’s appointment of Dr. Sharma is not a standalone event but the capstone of a meticulously executed expansion into cardiology. The company, which recently closed a $77 million Series C funding round partly earmarked for this purpose, has been making aggressive moves. This includes the recent acquisition of three established cardiology research sites from NextStage Clinical Research in Texas and a strategic partnership with US Heart & Vascular (USHV) to embed research capabilities within its network of community-based practices.

These moves position Iterative Health in a fiercely competitive market populated by global contract research organizations (CROs) like IQVIA and Labcorp, as well as a growing ecosystem of AI-focused health-tech startups. In this environment, differentiation is key. While many competitors offer either large-scale operational capacity or niche technology solutions, Iterative Health is building a hybrid model that combines a network of over 100 research sites with proprietary AI tools. The goal is to accelerate trials by improving site performance and patient recruitment.

Bringing Dr. Sharma into the fold provides the company with an invaluable asset: unparalleled clinical credibility. A Master Interventionalist of the Society for Cardiovascular Angiography and Interventions (MSCAI), Dr. Sharma is celebrated for pioneering the Rotablator technique for complex coronary blockages and performs over 1,600 complex interventions annually with a success rate exceeding 99%. His leadership as Director of the Cardiovascular Clinical Institute at Mount Sinai gives him a vantage point that spans both cutting-edge academic research and high-volume clinical practice. For Iterative Health, his involvement is a powerful endorsement that can attract top-tier research sponsors and instill confidence across its growing network of clinical sites.

Closing the 'Bedside-to-Trial' Gap

In the press release, Dr. Sharma pointed to a core industry problem: "There's a real gap between what a trial protocol asks for and what's actually workable at the bedside, and it can cost a study valuable time.” This single statement encapsulates a multi-billion-dollar challenge for the pharmaceutical and medical device industries. Trial protocols, often designed in the sterile environment of a sponsor’s headquarters, can be notoriously difficult to implement in a busy clinical setting.

Cardiology trials are particularly susceptible to this disconnect. They often involve patients with multiple comorbidities—such as diabetes or kidney disease—and strict eligibility criteria that can lead to high screen-failure rates. A protocol that seems sound on paper may prove unworkable when faced with the logistical constraints of a community clinic or the complex medical histories of real-world patients. This friction leads to slow enrollment, costly delays, and a research pipeline that moves far slower than the patient need it aims to address.

This is the gap Iterative Health was built to close. The company's model focuses on providing its network sites with operational support, training, and AI-powered tools for pre-screening patient records to identify potential trial candidates. The strategy is to reduce the administrative burden on clinical staff and make participation in research more feasible. Dr. Sharma's role is to provide the clinical wisdom that makes this model work. With his decades of experience, he can vet trial protocols for their practicality, ensuring they are not only scientifically rigorous but also operationally viable. His guidance can help refine eligibility criteria and study procedures before a trial even begins, preventing costly missteps and aligning research goals with the realities of patient care.

The Synergy of AI and Human Expertise

At the heart of this story is the powerful synergy between artificial intelligence and irreplaceable human expertise. Iterative Health's platform leverages AI to sift through vast amounts of clinical data, streamlining the arduous process of identifying eligible patients for complex trials. This technological horsepower is essential for achieving scale and efficiency across a distributed network of research sites.

However, technology alone is not a panacea. AI algorithms are only as good as the data they are trained on and the logic that governs them. Without deep domain expertise, a technology platform risks optimizing for the wrong variables or creating protocols that are clinically unsound. This is where Dr. Sharma's contribution becomes indispensable.

With over 350 peer-reviewed articles and a career built on tackling the most challenging cardiovascular cases, his expertise provides the essential clinical context that AI lacks. He understands the nuances of patient presentation, the subtleties of disease progression, and the practical challenges of implementing a given procedure. The collaboration promises a model where AI handles the heavy lifting of data processing and operational logistics, freeing up human experts like Dr. Sharma to focus on the high-level strategic decisions that define a successful trial: refining the research question, ensuring patient safety, and interpreting the clinical significance of the results. This fusion of scalable technology and deep, earned wisdom represents a new frontier in trial execution.

The Ripple Effect on Research and Patient Care

Ultimately, the success of this partnership will be measured by its impact on patients. Cardiovascular disease remains the leading cause of death globally, affecting nearly half of all adults in the United States. The demand for new, more effective therapies is urgent, yet the traditional clinical trial model remains a significant bottleneck.

By embedding research into community care settings through its partnerships with organizations like USHV, Iterative Health is already working to make clinical trials more accessible to diverse patient populations who live outside the orbit of major academic medical centers. The addition of Dr. Sharma's leadership is poised to accelerate this effort. His reputation can help attract more community-based practices to the research enterprise, while his expertise can ensure that the trials conducted within this network are of the highest quality.

For an industry grappling with how to innovate faster, the model being built by Iterative Health offers a compelling blueprint. It suggests that the future of clinical research lies not in a battle between technology and tradition, but in a thoughtful integration of both. By pairing a sophisticated AI platform with the guidance of a clinical master, the company is making a powerful argument that the best way to accelerate innovation is to ensure it remains firmly grounded in the realities of clinical practice and the needs of the patient.